Epidarex Capital Portfolio Company Apellis Pharmaceuticals Completes Initial Public Offering
In All, PortfolioBethesda, Maryland, USA, and Edinburgh, UK: Epidarex Capital (“Epidarex”), an early-stage, transatlantic life science venture fund, is pleased to announce the initial public offering (“IPO”) of its portfolio company Apellis Pharmaceuticals, Inc. (“Apellis”), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds…